Vale reported Q3 pro forma EBITDA of $3.51B, down 20% Y/Y and 14% Q/Q but above analyst expectations, and net operating ...

Artificial Intelligence is going to be something that changes the economy, according to San Francisco Federal Reserve Bank ...

Over the past decade, November has established itself as the undisputed seasonal juggernaut for the benchmark fund, ...

Gilead Sciences posts its strongest growth in a decade, led by HIV drugs. Click for this GILD earnings update and a look at ...

November market outlook: rising Treasury yields, volatile oil, and political risks shaping AI, crypto, defense, and energy.

Is the AI boom reaching a breaking point? Larry McDonald discusses growing cracks in the AI trade, warning signs in credit ...

ServiceNow experienced a sharp 30%+ sell-off, primarily driven by market disappointment in cRPO guidance despite robust Q3 ...

Regeneron enters a new growth cycle after a strong Q3, with Dupixent, Eylea HD, and pipeline momentum boosting the outlook.

See how rising memory costs, cash flow pressure, and chart weakness could hit Nvidia Corporation stock, though there may be ...

Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a ...

Nektar’s rezpegaldesleukin enters phase 3 in atopic dermatitis, with Q1 2027 data ahead. Discover more here on NKTR and our ...

JELD-WEN Holding remains a Sell due to deteriorating fundamentals, high leverage, and persistent revenue declines. Read more ...